Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience
Trending
- Many cancer survivors have impairments that make using mobile devices and websites difficult
- Clinical Scenarios: Matching Regimen to Patient Profile
- Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls
- Debunking the biggest myths about sun safety – Cancer Research UK
- Boy, 13 one of Scotland’s first to undergo innovative brain surgery
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets
- Dual-targeting pharmacological UFMylation inhibition reprograms tumor and immune microenvironments to achieve long-term glioblastoma regression
- Pan-cancer proteogenomic interrogation of the ubiquitin-proteasome system

